Skip to content

Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients

Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00622934
Acronym
EPREX
Enrollment
20
Registered
2008-02-25
Start date
2007-07-31
Completion date
2008-05-31
Last updated
2010-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Trauma

Keywords

multiple trauma

Brief summary

The purpose of this study is to determine whether Erythropoietin decrease stress responses and inflammation in trauma patient.

Detailed description

Transfusion of blood products has many disadvantages. Erythropoietin is used to increase red blood cells production and decrease such disadvantages.In some studies anti inflammatory effects is shown for Erythropoietin. One of the most problems in the intensive care unit is stress response. we are going to evaluate effects of erythropoietin on oxidative stress and inflammation in trauma patient in intensive care unit.

Interventions

DRUGerythropoietin

300mg/kg erythropoietin 3 times on the first week of admission

DRUGplacebo

placebo

Sponsors

Tehran University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* All multiple trauma patients\>16 years with informed consent

Exclusion criteria

* Hypertension * Allergy * Erythroid leukemia * Pregnancy and breast feeding * Pre operative patient * Severe cardiovascular and cerebrovascular diseases * Thromboembolic disorders

Design outcomes

Primary

MeasureTime frame
apachi 2 saps 30 days mortalityuntill discharge

Secondary

MeasureTime frame
30 days mortality30 days

Countries

Iran

Contacts

Primary Contactmojtaba mojtahedzade
Mojtahed@sina.tums.ac.ir0982166701041
Backup Contactmostafa mohammady
mohammady_m2007@yahoo.com0982166735017

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026